Global MedTech innovations continue to surge with record levels of R&D across all geographies. As a result, record numbers of MedTech patents have been issued within the US, Europe and Japan. However, as companies commercialize these innovations, they are often faced with significant challenges when attempting to enter China, the second largest MedTech market in the world by revenue size.
Constellation Life Sciences (“CLS”), with our established, in-country management team and network of partners, is your ideal China commercialization arm. We will invest, navigate through the evolving regulatory landscape, develop a commercialization path, protect your intellectual property, manage your go-to-market and maximize your China revenues.
Historically, multinationals have done well importing high-end MedTech products and local companies have played in the lower-valued consumables and “me-too” segments. However, recent policy changes are pushing both multinational companies and local players into a new China MedTech segment – Local Premium. But, the path to “Local Premium” is challenge to both MNCs and local players, requiring new partnership models.